Consistent with the association of its increased expression with resistance to many agents in our pancancer analysis, PHDLA2 had been previously found to be a part of molecular signatures and pathways overexpressed in melanoma and multiple myeloma cell lines resistant to a BRAF inhibitor/MEK inhibitor combination and proteasome inhibitors, respectively [121, 122]. This evidence concerns the gene MAP2K7 and melanoma.